EPHB4 and cancer: These results suggest that AP8901 therapy may become a new therapeutic option, with high efficacy, in patients with EPHB4-positive solid tumors for whom there is currently no established standard of care, especially solid tumors such as Ewing sarcoma and other cancers with high EPHB4 expression detected by immunohistochemistry.